Ribomic Inc.
4591.T
Get informed when a big investor buys or sells
+ FollowMarket Cap$3.97B
Close$
$38.21
46.2% downside
Current Fair Value
46.2% downsideOvervalued by 46.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $3.97 Billion |
|---|---|
| Enterprise Value | $1.99 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-23.07 |
| Beta | 0.19 |
| Outstanding Shares | 55,590,245 |
Return
| Return on Equity | -43.34% |
|---|---|
| Return on Assets | -41.09% |
| Return on Invested Capital | -44.81% |
Valuation & Multiples
| P/E Ratio | -3.11 |
|---|---|
| PEG | -16.23 |
| Price to Sales | - |
| Price to Book Ratio | 1.45 |
| Enterprise Value to Revenue | 265.59 |
| Enterprise Value to EBIT | -1.62 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 13, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 12, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Ribomic Inc.
25 employees
CEO: Yoshikazu Nakamura Ribomic Inc. is a Japanese biopharmaceutical company dedicated to identifying and advancing medicinal compounds. The firm employs RNA aptamers in its drug development efforts, targeting various significant health issues such as wet age-r...